Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; Division of Surgery and Interventional Sciences, University College London, London, UK; Department of Urology, University College London Hospital (UCLH), UK.
Department of Radiotherapy, University Medical Centre, Utrecht, The Netherlands.
Eur Urol Focus. 2021 Mar;7(2):301-308. doi: 10.1016/j.euf.2019.09.004. Epub 2019 Oct 5.
The oncological outcomes in men with clinically significant prostate cancer following focal cryotherapy are promising, although functional outcomes are under-reported.
To determine the impact of focal cryotherapy on urinary and sexual function, specifically assessing return to baseline function.
DESIGN, SETTING, AND PARTICIPANTS: Between October 2013 and November 2016, 58 of 122 men who underwent focal cryotherapy for predominantly anterior clinically significant localised prostate cancer within a prospective registry returned patient-reported outcome measure questionnaires, which included International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-15) questionnaires.
Standard cryotherapy procedure using either the SeedNet or the Visual-ICE cryotherapy system.
Primary outcome was return to baseline function of IPSS score and IIEF erectile function (EF) subdomain. Cumulative incidence and Cox-regression analyses were performed.
Probability of returning to baseline IPSS function was 78% at 12 mo and 87% at both 18 and 24 mo, with recovery seen up to 18 mo. For IIEF (EF domain), the probability of returning to baseline function was 85% at 12 mo and 89% at both 18 and 24 mo, with recovery seen up to 18 mo. Only the preoperative IIEF-EF score was associated with a poor outcome (hazard ratio 0.96, 95% confidence interval 0.93-0.999, p = 0.04). The main limitation was that only half of the patients returned their questionnaires.
In men undergoing primary focal cryotherapy, there is a high degree of preservation of urinary and erectile function with return to baseline function occurring from 3 mo and continuing up to 18 mo after focal cryotherapy.
In men who underwent focal cryotherapy for prostate cancer, approximately nine in 10 returned to their baseline urinary and sexual function. Keeping in mind that level 1 evidence and long-term data are still needed, in men who wish to preserve urinary and sexual function, focal cryotherapy may be considered an alternative treatment option to radical therapy.
对于患有临床显著前列腺癌的男性,采用局部冷冻治疗后的肿瘤学结果是有希望的,尽管功能结果的报道较少。
确定局部冷冻治疗对尿功能和性功能的影响,特别是评估恢复到基线功能的情况。
设计、设置和参与者:2013 年 10 月至 2016 年 11 月,在一个前瞻性登记处,122 名接受主要为前侧局部临床显著前列腺癌的局部冷冻治疗的男性中,有 58 名返回了患者报告的结局测量问卷,其中包括国际前列腺症状评分(IPSS)和国际勃起功能指数(IIEF-15)问卷。
使用 SeedNet 或 Visual-ICE 冷冻治疗系统进行标准冷冻治疗程序。
主要结局是 IPSS 评分和 IIEF 勃起功能(EF)子域的基线功能恢复。进行了累积发生率和 Cox 回归分析。
在 12 个月时,恢复到 IPSS 功能基线的概率为 78%,在 18 个月和 24 个月时均为 87%,在 18 个月时可见恢复。对于 IIEF(EF 域),恢复到基线功能的概率为 12 个月时为 85%,18 个月和 24 个月时均为 89%,在 18 个月时可见恢复。只有术前 IIEF-EF 评分与不良结局相关(风险比 0.96,95%置信区间 0.93-0.999,p=0.04)。主要局限性在于只有一半的患者返回了他们的问卷。
在接受原发性局部冷冻治疗的男性中,尿功能和勃起功能的保存程度很高,在接受局部冷冻治疗后 3 个月开始恢复,并持续至 18 个月。
在接受前列腺癌局部冷冻治疗的男性中,约十分之九的人恢复了他们的基线尿功能和性功能。考虑到仍需要 1 级证据和长期数据,对于希望保留尿功能和性功能的男性,局部冷冻治疗可能是作为根治性治疗的替代治疗选择。